Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Cash & Current Investments (2019 - 2023)

Alx Oncology Holdings' Cash & Current Investments history spans 5 years, with the latest figure at $190.0 million for Q3 2023.

  • For Q3 2023, Cash & Current Investments fell 33.31% year-over-year to $190.0 million; the TTM value through Sep 2023 reached $190.0 million, down 33.31%, while the annual FY2022 figure was $266.2 million, 26.8% down from the prior year.
  • Cash & Current Investments for Q3 2023 was $190.0 million at Alx Oncology Holdings, down from $212.8 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $434.2 million in Q4 2020 and bottomed at $9.0 million in Q4 2019.
  • The 5-year median for Cash & Current Investments is $284.9 million (2022), against an average of $280.1 million.
  • The largest annual shift saw Cash & Current Investments surged 4715.56% in 2020 before it plummeted 33.31% in 2023.
  • A 5-year view of Cash & Current Investments shows it stood at $9.0 million in 2019, then soared by 4715.56% to $434.2 million in 2020, then decreased by 16.25% to $363.7 million in 2021, then fell by 26.8% to $266.2 million in 2022, then decreased by 28.62% to $190.0 million in 2023.
  • Per Business Quant, the three most recent readings for ALXO's Cash & Current Investments are $190.0 million (Q3 2023), $212.8 million (Q2 2023), and $227.9 million (Q1 2023).